AMCP Partnership Forum Examines Principles for Sound P&T Practices: What’s Next?
Diverse stakeholders gathered last week to discuss the future of P&T committee processes at the AMCP Partnership Forum, Principles for Sound Pharmacy and Therapeutics (P&T) Practices: What’s Next? The March 28 event sought to promote and advance P&T best practices for an evolving health care system, said AMCP CEO Susan A. Cantrell, RPh, CAE.
“It’s not an overstatement to say that P&T committees represent the very foundation of managed care pharmacy,” Cantrell said. “The informed decisions that stem from a P&T committee’s scientific assessment of products allows us to carry out our mission of ensuring all patients have access to needed medications, while also remaining good stewards of limited health care dollars.”
Over the years, P&T committees have become a common fixture across the health care spectrum, including in Medicare Part D programs, health insurance marketplace plans, commercial health plans, and Medicaid programs. In the nearly 20 years since AMCP and other stakeholders adopted the Principles for a Sound Formulary System, the evolution in health care suggests the need for an update. As such, the Forum sought to:
- Identify how P&T committees are evaluating different types of evidence, and what role exists for additional types of information, such as real-world evidence and patient-reported outcomes;
- Identify ways for the P&T committee composition and process to support value-based care;
- Consider ways to resolve potential conflicts of interest in the P&T process and support transparency; and
- Provide recommendations for updating the P&T process to stay current with changes and advances in care.
AMCP will gather the recommendations and identify actionable steps that AMCP and other stakeholders may take to promote and advance P&T best practices. The recommendations will be published in a proceedings document later this year in the Journal of Managed Care & Specialty Pharmacy. Forum attendees included representatives of patients, payers, providers, government, and biopharmaceutical companies. Sponsors for the event were Amgen, Genentech, Merck, National Pharmaceutical Council, Novo Nordisk, Pharmaceutical Research and Manufacturers of America, Precision for Value and Takeda.